Share Price:

APNASPENAspen Pharmacare Hldgs10752-189 (-1.73%)

Aspen is in a closed period from 1st January 2026 until the publication of the interim results on the JSE SENS platform on the 3rd March 2026.

Boehringer Ingelheim grants a voluntary license for nevirapine to South African company Aspen Pharmacare

South Africa – Boehringer Ingelheim South Africa announced today that it has granted a voluntary license to the South African pharmaceutical manufacturer Aspen Pharmacare for the production, distribution and sale of the antiretroviral nevirapine (marketed world wide by Boehringer Ingelheim as VIRAMUNE). It is the first time that Boehringer Ingelheim has granted a non-exclusive voluntary… Continue reading Boehringer Ingelheim grants a voluntary license for nevirapine to South African company Aspen Pharmacare

Closed Period

Aspen is in a closed period from 1st January 2026 until the publication of the interim results on the JSE SENS platform on the 3rd March 2026.

The live presentation will take place in Cape Town at 08h30 on 2 March 2023.

Corporate

Our career opportunities are across the corporate spectrum, including Human Capital, Digital Technology, Legal, and Risk & Sustainability. Our employees are given the opportunity to hone their skills and develop the experience of excellence in their chosen field in the pharmaceutical industry.

View our teams below: